Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in patients with tuberculosis-associated chronic obstructive pulmonary disease: study protocol for a randomised controlled trial

Read full text Summarise with VIRAT
Authors: Fan Wu, Suyin Huang, Ming Lei, Zhishan Deng, Qi Wan, Gaoying Tang, Kunning Zhou, Xiaoyan Liang, Tuxunguli Abduwaiti, Reyihanguli Turgon, Kaiqing Zhang, Kailibinur Turgon
+3 more Yanni Li, Haiqing Li, Weifeng Zou
Cited by: 0
References: 47

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Clinical trials have shown that glycopyrrolate/formoterol fumarate improves lung function in patients with chronic obstructive pulmonary disease (COPD) caused by tobacco exposure. Although tuberculosis-associated COPD has worse respiratory health outcomes than smoking-associated COPD, no clinical trials have determined whether pharmacological intervention is effective. We designed a clinical trial to evaluate the safety and efficacy of glycopyrrolate/formoterol fumarate for the treatment of tuberculosis-associated COPD. Methods: , FVC, and percentage predicted FVC; and COPD Assessment Test scores. Discussion: The results of the PTB-COPD trial will provide the first insights into the pharmacological treatment of tuberculosis-associated COPD. We anticipate the results of this trial to be available in the first half of 2027. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2500103088. Registered on May 23, 2025.

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Inhalation and Respiratory Drug Delivery Asthma and respiratory diseases

Publication details

Journal / source
Journal of Thoracic Disease
Volume
18
Issue
3
Pages
256–256
Publication date
1 March 2026
Language
EN